[Treatment of acute lymphoblastic leukemia in children during remission with a sequential chemotherapy followed by an active immunotherapy trial].
D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001500:BCG Vaccine; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use*; D011809:Quinones / Q000627:therapeutic use; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D007166:Immunosuppressive Agents; D011809:Quinones; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone
Traitement de la leucemie aigue lymphoblastique de l'enfant pendant la remission par une chimiotherapie sequentielle suivie d'un essai d'immunotherapei active.